☆ 4.4 Article

Standards of Fluid Biomarker Collection and Pre-analytical Processes in Humans and Mice: Recommendations by the Ataxia Global Initiative Working Group on Biomarkers

CEREBELLUM (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Inge M. W. Verberk et al.

Summary: Pre-analytical sample handling can impact Alzheimer's disease blood-based biomarkers. Different collection tube types resulted in varying values of assessed markers, with delayed centrifugation and storage affecting A beta and t-tau. Standardized operating procedures for plasma handling were constructed to facilitate the incorporation of blood-based biomarkers into research and clinical settings.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Clinical Neurology

Blood Neurofilament Light Chain in Genetic Ataxia: A Meta-Analysis

Linliu Peng et al.

Summary: The study confirms the potential of NfL as a biomarker in genetic ataxia, predicting disease onset, severity, and progression. Reference-range setting of bNfL should be divided according to age.

MOVEMENT DISORDERS (2022)

Add to Collection

Editorial Material Clinical Neurology

Paving the Way Toward Meaningful Trials in Ataxias: An Ataxia Global Initiative Perspective

Thomas Klockgether et al.

MOVEMENT DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type

Carlo Wilke et al.

Summary: The study investigates the potential use of neurofilament light (NfL) as a biomarker in repeat-expansion spinocerebellar ataxias (SCAs). The findings suggest that NfL levels are increased not only in the ataxic stage of SCA1 but also in its preataxic stage. The study highlights the potential of using NfL as a sensitive marker for early neurodegeneration in SCA1.

NEUROLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status

Dorota Konickova et al.

Summary: The understanding of neurodegenerative diseases has shifted in the past 20 years, from being seen as well-defined entities to complex and heterogeneous processes. Diagnosis primarily requires brain imaging techniques or invasive tests, but identifying specific proteinopathies is difficult due to overlap in clinical diagnoses. Laboratory methods to identify biomarkers are urgently needed to improve diagnosis, monitor disease progression, and evaluate treatment effects.

BIOMEDICINES (2022)

Add to Collection

Article Clinical Neurology

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Ris E. Jansen et al.

Summary: This study found that levels of A beta 42 and pTau in cerebrospinal fluid are more direct indicators of the pathogenesis of Alzheimer's disease than clinical diagnosis. Through a collaborative effort, novel associations with AD risk loci and multiple biological pathways related to A beta 42 and pTau were identified.

ACTA NEUROPATHOLOGICA (2022)

Add to Collection

Review Multidisciplinary Sciences

Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis

Liangxia Ning et al.

Summary: This meta-analysis assessed the diagnosis and predictive value of blood neurofilament light chain (NfL) in multiple sclerosis (MS). The results suggest that blood NfL may be a useful biomarker in diagnosing MS, distinguishing MS subtypes, and predicting disease worsening in the future.

PLOS ONE (2022)

Add to Collection

Article Clinical Neurology

Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy

Takayuki Katayama et al.

Summary: This study explored the potential of cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels as biomarkers for neurodegeneration in different neurodegenerative diseases. It found elevated CSF NSE levels in AD and PDD/DLB, with age affecting NSE levels in AD patients.

ALZHEIMERS RESEARCH & THERAPY (2021)

Add to Collection

Article Clinical Neurology

Role of Blood Neurofilaments in the Prognosis of Amyotrophic Lateral Sclerosis: A Meta-Analysis

Yan-ni Zhou et al.

Summary: A meta-analysis revealed that higher blood neurofilament levels in ALS patients are associated with a greater risk of death and positively correlated with disease progression rate.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development

Meng-Ling Chen et al.

Summary: Spinocerebellar ataxias (SCAs) are a group of dominantly-inherited cerebellar ataxias, with CAG expansion-related SCAs being the most common. These diseases have high penetrance and defined disease progression, with emerging therapies being developed. Incorporating biomarkers into clinical trial design is crucial to test target engagement or track disease progression in response to therapies, especially in rare diseases such as SCAs.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood

Jeannette Huebener-Schmid et al.

Summary: An ultrasensitive immunoassay was developed to quantify polyQ-expanded ataxin-3 in plasma and CSF, showing stability and correlation with disease severity. Longitudinal analyses demonstrated high stability of polyQ-expanded ataxin-3 over a short period of time.

MOVEMENT DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3

Yuka Koike et al.

Summary: This study found that polyQ ATXN3 can be detected in the urine of SCA3 patients, serving as a potential biomarker for the disease. The levels of polyQ ATXN3 in urine are correlated with those in plasma and associated with an earlier age of onset of SCA3.

PARKINSONISM & RELATED DISORDERS (2021)

Add to Collection

Review Clinical Neurology

The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias

Andreas Traschuetz et al.

Summary: ARCAs form a rare group of neurodegenerative diseases, the ARCA Registry is a global multicenter platform aiming to advance trial readiness for ARCAs, providing GCP- and GDPR-compliant professional-reported registry with modular eCRFs for data capture tailored to different site interests and resources.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Spinocerebellar ataxia clinical trials: opportunities and challenges

Sarah M. Brooker et al.

Summary: SCAs are dominantly inherited diseases characterized by progressive cerebellar ataxia, affecting not only the cerebellum but also other areas of the brain; currently, there are no disease-modifying treatments available, but preclinical research has led to the development of potential therapeutic agents for testing in patients.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice

Carlo Wilke et al.

EMBO MOLECULAR MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study

Heike Jacobi et al.

LANCET NEUROLOGY (2020)

Add to Collection

Review Neurosciences

Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies

Matthis Synofzik et al.

NEURON (2019)

Add to Collection

Review Oncology

The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology

Daniel N. Cagney et al.

NEURO-ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Stability of Circulating Blood-Based MicroRNAs - Pre-Analytic Methodological Considerations

Charlotte Glinge et al.

PLOS ONE (2017)

Add to Collection

Review Clinical Neurology

Advances in Sequencing Technologies for Understanding Hereditary Ataxias A Review

Alessandro Didonna et al.

JAMA NEUROLOGY (2016)

Add to Collection

Review Clinical Neurology

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

Sid E. O'Bryant et al.

ALZHEIMERS & DEMENTIA (2015)

Add to Collection

Review Clinical Neurology

Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond

Alexandra Durr

LANCET NEUROLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.